• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

November 30, 2012
CenterWatch Staff

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

Sanofi obtains an exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies each to a specific food or aeroallergen. The products resulting from this collaboration will leverage Selecta's proprietary Synthetic Vaccine Particle (SVP) platform which is capable of engineering nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens.

In addition, Selecta is eligible to receive several pre-clinical, clinical, regulatory and sales milestones totaling $300 million per allergen indication for up to three immunotherapy candidates contemplated by this collaboration. Selecta is also entitled to up to double-digit tiered royalties as percentage of product net sales for each commercialized immunotherapy.

"We are very pleased that Sanofi, a global leader in vaccines and immunology, is entering into a partnership with Selecta to develop and commercialize products from our immunotherapy platform," said Werner Cautreels, PhD, president and CEO of Selecta. "In allergies, as well as auto-immune diseases, organ transplantation  and protein replacement therapies, there is a lack of specific, effective and safe treatments to prevent undesired immune reactions. Selecta's SVP technology can restore balance to dysregulated immune systems by producing immune tolerance to specific antigens. Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today's symptomatic treatments and allergen avoidance strategies."

The collaboration is aligned with Sanofi's strategic focus areas in immunology and leverages Sanofi's Boston-based research and development capabilities.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing